BofAS raised its rating for AKESO due to strong data from the HARMONi-6 study, which is the first time a Chinese-developed oncology drug has been selected for the ASCO Plenary Session. The broker increased the probability of success for the drug's indication in China and globally, leading to higher revenue and net profit forecasts for 2026-2028. The target price was also raised, and the Buy rating was reiterated based on robust clinical data and upcoming catalysts.
